First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response

Walter Taal, Erik jan Dubbink, CBL Zonnenberg, BA Zonnenberg, TJ Postma, JMM Gijtenbeek, W Boogerd, Floris Groenendijk, J.M. Kros, Mathilde Kouwenhoven, Ronald van Marion, Heuvel, Ronnie van der Holt, Jacoline Bromberg, Peter Sillevis Smitt, Winand Dinjens, Martin van den Bent

Research output: Contribution to journalArticleAcademicpeer-review

57 Citations (Scopus)

Abstract

Only a few studies examined the effect of temozolomidc (TMZ) in recurrent low-grade astrocytoma (LGA) after surgery, none of which included a homogeneous and sufficiently sized group of patients with progression after radiotherapy (RT). We evaluated a cohort of 58 patients treated with TMZ for progression after RT of a previous LGA and investigated the relation between outcome and mutations in the IDH1, IDH2, and TPS3 genes, O-6-methylguanine-methyltransferase (MGMT) promoter methylation, trisomy of chromosome 7, and loss of chromosomes 1 p and 19q. All patients received first-line TMZ 200 mg/m(2)/day on days 1-5 every 4 weeks for a progressive LGA with a contrast-enhancing lesion on MRI after RT. Six months progression-free survival (PFS) was 67%, and the median overall survival was 14 months. An objective response was obtained in 54%. TP53 mutations and loss of chromosome 19q showed a borderline association with PFS, but none of the other molecular characteristics were correlated with the outcome to TMZ. Both a methylated MGMT promoter gene and IDH1 mutations were found in 86% of the tumor samples. A correlation was found between IDH1 mutations and MGMT promoter methylation (P < .001). Neither MGMT promoter methylation nor IDHI mutations correlated with PFS, but the interval between the very first symptom of the LGA and the start of the TMZ was significantly longer in the patients with IDH1 mutations (P = .01) and a methylated MGMT promoter (P = .02). We conclude that MGMT promoter methylation and IDH1 mutations seem to predict survival from the time of diagnosis, but not PFS to TMZ.
Original languageUndefined/Unknown
Pages (from-to)235-241
Number of pages7
JournalNeuro-Oncology
Volume13
Issue number2
DOIs
Publication statusPublished - 2011

Cite this